ES

Elizabeth Stoner

Dr Stoner has over 30 years of experience in the life-science sector. She is currently an executive partner at MPM Capital, a US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including Antiva, and Rhythm Pharmaceuticals. Additionally, Dr Stoner served as the interim CEO of Semma Therapeutics. Prior to joining MPM Capital, Dr Stoner was a Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ALA
ALA
24/11/251,920,804N/A5,772,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ALA
ALA
24/11/25
Buy
1,157,647$0.083$96,084Exercise of options
ALA
ALA
24/11/25
Expiry
1,242,353$0.083$103,115Options expired
ALA
ALA
24/11/25
Exercise
1,157,647$0.083$96,084Exercise of options
ALA
ALA
26/11/24
Issued
354,000$0.185$65,490Director remuneration
ALA
ALA
04/12/23
Issued
618,000$0.088$54,384Director remuneration